Kestra Medical Technologies (NASDAQ:KMTS) CFO Vaseem Mahboob Sells 39,903 Shares of Stock

Key Points

• CFO Vaseem Mahboob sold 39,903 KMTS shares at an average price of $30.48, generating approximately $1.22 million and reducing his position by 39.7% to 60,609 shares.
• Kestra Medical Technologies’ stock traded near its 52-week high at $30.61, while the company reported a quarterly loss of $0.75 per share—worse than analysts’ expected loss of $0.61—on $30.97 million in revenue.
• Analyst sentiment remains moderately positive, with five Buy, two Hold and one Sell rating and an average price target of $29.00; the company develops wearable defibrillator and cardiac-monitoring technology.

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) CFO Vaseem Mahboob sold 39,903 shares of the stock in a transaction that occurred on Wednesday, October 28th. The stock was sold at an average price of $30.48, for a total value of $1,216,243.44. Following the completion of the transaction, the chief financial officer owned 60,609 shares in the company, valued at approximately $1,847,362.32. The trade was a 39.70% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Vaseem Mahboob also recently made the following trade(s):

• On Tuesday, October 27th, Vaseem Mahboob sold 34,809 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $30.04, for a total value of $1,045,662.36.
• On Thursday, October 29th, Vaseem Mahboob sold 4,788 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $30.60, for a total transaction of $146,512.80.
• On Friday, August 7th, Vaseem Mahboob sold 26,287 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $25.88, for a total value of $680,307.56.
• On Tuesday, August 4th, Vaseem Mahboob sold 6,995 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $24.68, for a total value of $172,636.60.
• On Monday, August 3rd, Vaseem Mahboob sold 5,391 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $23.80, for a total transaction of $128,305.80.
• On Friday, July 31st, Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.61, for a total value of $199,352.37.

Kestra Medical Technologies Stock Performance

KMTS traded up $0.74 during trading hours on Thursday, hitting $30.61. The stock had a trading volume of 470,598 shares, compared to its average volume of 351,886. The company's fifty day simple moving average is $26.59 and its 200 day simple moving average is $23.76. Kestra Medical Technologies, Ltd. has a 1 year low of $17.34 and a 1 year high of $31.04. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.33. The stock has a market cap of $1.82 billion, a PE ratio of -11.46 and a beta of 0.51.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last posted its earnings results on Monday, September 14th. The company reported ($0.75) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.14). Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. The company had revenue of $30.97 million for the quarter. Equities analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.45 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on KMTS shares. BTIG Research restated a "buy" rating and set a $32.00 price target on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. Wolfe Research set a $30.00 price objective on shares of Kestra Medical Technologies in a research report on Wednesday, July 15th. Oppenheimer started coverage on Kestra Medical Technologies in a research report on Tuesday, July 21st. They set a "market perform" rating on the stock. Wall Street Zen downgraded Kestra Medical Technologies from a "hold" rating to a "sell" rating in a research note on Saturday, September 12th. Finally, Piper Sandler restated an "overweight" rating on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $29.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of KMTS. Sterling Capital Management LLC lifted its holdings in shares of Kestra Medical Technologies by 834.0% in the 3rd quarter. Sterling Capital Management LLC now owns 878 shares of the company's stock valued at $25,000 after acquiring an additional 784 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Kestra Medical Technologies during the 3rd quarter valued at about $353,000. Quantinno Capital Management LP bought a new position in Kestra Medical Technologies in the 1st quarter valued at $431,000. California State Teachers Retirement System boosted its position in Kestra Medical Technologies by 39.2% in the 1st quarter. California State Teachers Retirement System now owns 27,835 shares of the company's stock valued at $555,000 after buying an additional 7,844 shares during the period. Finally, Spartan Wealth Advisory Services LLC purchased a new stake in shares of Kestra Medical Technologies in the 1st quarter worth $603,000.

About Kestra Medical Technologies

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient's heart rhythm and deliver a therapeutic shock when clinically necessary.

The company's platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.